Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
2 evidence topics · 30 sources
Summary: limitations of active surveillance and local therapies
- Active surveillance: in a pooled analysis of 282 participants, 93 (33.0%) received active treatment after initial surveillance, and the 5-year crude cumulative incidence of RECIST progression was 34%. In a United Kingdom cohort of 168 participants, 46% proceeded to treatment, for pain (32%), progression (31%), or both (13%). Guidelines call for a first MRI within 1-2 months and then imaging at 3-6 month intervals, and surveillance may not be appropriate if progression could “be life-threatening or pose a risk for mutilation”.
- Surgery: NCCN and Desmoid Tumor Working Group guidelines “no longer support surgery as the first-line option in most situations” because of high postsurgical recurrence rates. Reported postsurgical recurrence reaches 50% to 88%, and 30%-90% for extremity tumors; after complete gross resection, 23% of patients had recurrence. In unfavorable locations, 2-year event-free survival was 25% after initial surgery and 52% with wait-and-see. Amputation was reported by 7% (12/163) of survey participants who had surgery, and 83% of them reported regrowth or recurrence afterward.
- Radiotherapy: in the EORTC 62991-22998 phase II trial (44 participants), the 3-year local control rate was 81.5% and response was slow. A review of 317 participants treated with definitive radiation reported local control in 79.8%, frequent late fibrosis, contracture, joint stiffness, skin disorders, lymphedema, and pain, and 6 secondary malignancies in the radiation field. The evidence for adjuvant radiotherapy is low, and it carries a risk of radiation-induced sarcoma “in this young patient population”.
- Ablation: in CRYODESMO-01 (50 participants), the 12-month non-progression rate was 86%, and grade 3-4 toxicity occurred in 22%. A systematic review of 146 participants reported major complications in 13.3-30%, and across 694 lesions treated with cryoablation, HIFU, or microwave ablation, severe nerve injury was the most common major complication (26.3%). Cryoablation is of limited use for larger tumors involving vital structures, and ablative approaches are not available in every center and require particular expertise.
Summary: limitations of systemic therapies
- Comparative evidence: the Desmoid Tumor Working Group stated that “due to the lack of comparative studies” no definitive sequence of systemic treatments could be proposed, with randomized data then existing for sorafenib, pazopanib, and methotrexate plus vinblastine. The NCCN guidelines (version 1.2025, as restated in a Cigna policy) list nirogacestat and sorafenib as category 1 and the other listed agents as category 2A.
- Gamma secretase inhibitors: in DeFi, dose reductions due to adverse events occurred in 42% of nirogacestat recipients (0% with placebo) and discontinuation due to adverse events in 20% (1% with placebo); ovarian dysfunction occurred in 27 of 36 women of childbearing potential (75%), with resolution reported in 78% (21 of 27) as of October 24, 2022, including all 11 who stopped treatment. The label carries warnings for diarrhea, ovarian toxicity, hepatotoxicity, non-melanoma skin cancers, electrolyte abnormalities, hypersensitivity reactions (added in August 2026), and embryo-fetal toxicity, and advises avoiding strong or moderate CYP3A inhibitors and inducers and gastric acid reducing agents. The appropriate treatment duration is unknown, and nirogacestat is “still not widely available outside of the United States”.
- Tyrosine kinase inhibitors are used off label and are not commissioned in the NHS in England for desmoid tumours. In the sorafenib phase 3 trial, adverse events led to discontinuation in 20% (no placebo patients), dose reductions due to toxic effects occurred in 31% vs 11%, and grade 1 or 2 rash occurred in 73%. In an 11-institution cohort of 142 participants treated with sorafenib or pazopanib, 59.9% discontinued treatment, mainly for toxicity. Imatinib trials showed response rates of 6–19%, and in DESMOPAZ grade 3 or 4 hypertension occurred in 21% of the pazopanib group.
- Chemotherapy is “not licensed for treating desmoid tumours” (NICE). Response rates are in the range of 35–40% and usually occur several months after the start of therapy. In DESMOPAZ, 45.0% of the methotrexate-vinblastine group had not progressed at 6 months, and neutropenia occurred in 45%. Systematic reviews reported grade 3 or 4 adverse event rates of 31% for low-dose methotrexate plus vinblastine and 28% for doxorubicin-based regimens, and grade 3 events were more frequent with anthracycline regimens than with sorafenib (27% vs 14%). NICE judged the hazard ratio of 0.05 for chemotherapy versus placebo in Xu et al. “implausibly large”, and experts stated that pegylated liposomal doxorubicin is not used for desmoid tumours in the UK.
- Hormonal therapy and NSAIDs: the Desmoid Tumor Working Group found “no evidence to consider antihormonal therapies and NSAIDs”, and hormone antagonists are no longer recommended in its consensus guidelines; NCCN lists sulindac or other NSAIDs for pain as useful in certain circumstances (category 2A). In a Children's Oncology Group phase II study of tamoxifen plus sulindac, responses occurred in 8% (5/59), 2-year PFS was 36%, and 12 of 30 females (40%) developed ovarian cysts. Toremifene 60 mg daily was ineffective (12-month PFS 4.8%), and the S45F mutation was associated with poor response to meloxicam.